Buzz surrounds new malaria drug, but the once-a-week wonder comes with a catch

The prophylactic agent causes side effects in patients with a certain deficiency

The TGA has approved a new once-a-week malaria prevention drug for international travellers.


Tafenoquine is the first new malaria prophylactic agent for 20 years, but there’s a catch: it can only be used if the patient does not have a G6PD deficiency.

The drug requires a three-day loading dose and a final dose one week after leaving a malaria-endemic region.

It will be available by prescription for adults next year, according to manufacturer Sixty Degrees Pharma, but the expected cost to patients is not yet known.

Tafenoquine (Kodatef) kills